Table II.
Prodrug cytotoxicity against SK-BR-3, MDA-MB-231, MCF-7, and +SA Breast Cancer Cell Lines. Cells Were Incubated 72 Hours with each Prodrug and Cell Viability was Assessed Through Alamar Blue Assay (n = 4)
| IC50 (nM ± SD) | ||||
|---|---|---|---|---|
|
|
||||
| SK-BR-3 | MDA-MB-231 | MCF-7 | + SA | |
| Paclitaxel 1 | 213 ± 92 | 326 ± 128a | 47.0 ± 18.1 | 93.9 ± 42.9 |
| PAX7′C6 4a | 91.7 ± 37.5 | 288 ± 94 | 60.1 ± 26.2 | 129 ± 28 |
| 4b | >1 μM | >1 μM | >1 μM | >1 μM |
| 4c | >1 μM | >1 μM | >1 μM | >1 μM |
| 5a | >1 μM | >1 μM | >1 μM | >1 μM |
| 5b | >1 μM | >1 μM | >1 μM | >1 μM |
| 5c | >1 μM | >1 μM | >1 μM | >1 μM |
| PAX7′C6 in micelles | – | 114 ± 30a | – | – |
a
Denotes statistical significant difference (P < 0.05) between paclitaxel and PAX7′C6, or paclitaxel and PAX7′C6 in micelles.